Raha Samraat S. 4

What Happened

• Raha Samraat S., President, CEO and director of Myriad Genetics (MYGN), acquired 3,542 shares on 2026-06-11 at $3.94 per share, for a total reported value of $13,941. The shares were purchased under Myriad’s Amended and Restated 2012 Employee Stock Purchase Plan (ESPP).

Key Details

• Transaction date: 2026-06-11; price: $3.94 per share; total value: $13,941.
• Transaction type/code: A — acquisition/award (ESPP purchase).
• Shares owned following the transaction: not specified in the filing.
• Footnote: the purchase was made under the issuer’s ESPP and was exempt under Rule 16b-3(d) and Rule 16b-3(c).
• Filing date: 2026-06-12 — appears timely (filed one day after the transaction).

Context

• This was an employee plan purchase (ESPP), not an option exercise or open-market trade. ESPP purchases are routine compensation/benefit transactions and are often treated differently from discretionary insider buys or sells. The exemption under Rule 16b-3 means the transaction met conditions that exclude it from short-swing profit recovery between insiders and the company.